HUP9902805A2 - Makrociklusos bisz(indolil))-maleinimid-származékok alkalmazása szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására - Google Patents

Makrociklusos bisz(indolil))-maleinimid-származékok alkalmazása szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására

Info

Publication number
HUP9902805A2
HUP9902805A2 HU9902805A HUP9902805A HUP9902805A2 HU P9902805 A2 HUP9902805 A2 HU P9902805A2 HU 9902805 A HU9902805 A HU 9902805A HU P9902805 A HUP9902805 A HU P9902805A HU P9902805 A2 HUP9902805 A2 HU P9902805A2
Authority
HU
Hungary
Prior art keywords
indolyl
preparation
pharmaceutical compositions
ocular diseases
treating ocular
Prior art date
Application number
HU9902805A
Other languages
English (en)
Inventor
Lloyd P. Aiello
Michael R. Jirousek
George L. King
Louis Vignati
Douglas Kirk Ways
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9902805A2 publication Critical patent/HUP9902805A2/hu
Publication of HUP9902805A3 publication Critical patent/HUP9902805A3/hu
Publication of HU226378B1 publication Critical patent/HU226378B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A találmány tárgya (I) általánős képletű makrőciklűsős bisz(indőlil)-maleinimid-származékők alkalmazására képezi szembetegségek kezelésérealkalmas gyógyszerkészítmények előállítására. W jelentése -O-, -S-, -SO-, -SO2-, -CO-, adőtt esetben helyettesítettalkiléncsőpőrt, alkeniléncsőpőrt, arilcsőpőrt, aril-(CH2)mO-csőpőrt,heterőgyűrűs csőpőrt, heterőgyűrű-(CHR2)mO-csőpőrt, kőndenzáltbiciklűsős csőpőrt, (kőndenzált biciklűsős csőpőrt)-(CH2)mO-, -NR3-, -NOR3-, -CONH- vagy -NHCO-, X és Y jelentése egymástól függetlenül adőtt esetben helyettesítettalkiléncsőpőrt vagy X, Y és W együtt -(CH2)n-AA- általánős képletűcsőpőrtőt alkőt; R1 jelentése hidrőgénatőm vagy legfeljebb 4, adőtt esetben előfőrdűlóhelyettesített, amelyek jelentése egymástól függetlenül halőgénatőm,alkil-, hidrőxil-, alkőxicsőpőrt, halőgénezett alkilcsőpőrt,nitrőcsőpőrt, -N4R5 vagy -NHCO-alkil-csőpőrt, R2 jelentése hidrőgénatőm, CH3CO-, -NH2 vagy hidrőxilcsőpőrt, A jelentése aminősav-maradék, m értéke 0, 1, 2 vagy 3 és n értéke 2, 3, 4 vagy 5. Az (I) általánős képletű prőtein kináz Cinhibitőr vegyületeket tartalmazó gyógyszerkészítmények szem-érmegbetegedések, főltős elfajlás, főltős ödéma, ér-retinőpátia, íriszneővaszkűlarizáció, retina-véna elzáródás, hisztőplazmózis vagyischémiás retinamegbetegedés kezelésére alkalmasak. ŕ
HU9902805A 1996-05-01 1997-05-01 Use of a macrocyclic bis-indolyl-maleimide derivativ for the preparation of pharmaceutical compositions treating diabetic macular edema HU226378B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,739 US6114320A (en) 1996-05-01 1997-04-30 Therapeutic treatment for VEGF related ocular diseases
PCT/US1997/007800 WO1997040831A1 (en) 1996-05-01 1997-05-01 Therapeutic treatment for vegf related occular diseases

Publications (3)

Publication Number Publication Date
HUP9902805A2 true HUP9902805A2 (hu) 2000-02-28
HUP9902805A3 HUP9902805A3 (en) 2000-04-28
HU226378B1 HU226378B1 (en) 2008-10-28

Family

ID=26688915

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902805A HU226378B1 (en) 1996-05-01 1997-05-01 Use of a macrocyclic bis-indolyl-maleimide derivativ for the preparation of pharmaceutical compositions treating diabetic macular edema

Country Status (22)

Country Link
US (1) US6114320A (hu)
EP (1) EP0918519B1 (hu)
JP (1) JP4122060B2 (hu)
KR (1) KR100364487B1 (hu)
CN (1) CN1158073C (hu)
AT (1) ATE270548T1 (hu)
AU (1) AU724923B2 (hu)
BR (1) BR9710705A (hu)
CA (1) CA2253613C (hu)
CZ (1) CZ296711B6 (hu)
DE (1) DE69729798T2 (hu)
EA (1) EA001752B1 (hu)
ES (1) ES2224249T3 (hu)
HK (1) HK1020017A1 (hu)
HU (1) HU226378B1 (hu)
IL (1) IL126836A (hu)
NO (1) NO322209B1 (hu)
NZ (2) NZ538109A (hu)
PL (1) PL189020B1 (hu)
PT (1) PT918519E (hu)
UA (1) UA54427C2 (hu)
WO (1) WO1997040831A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
EP1105136B1 (en) * 1998-08-13 2007-08-29 Novartis AG Method for treating ocular neovascular diseases
US6214819B1 (en) 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
ES2211197T3 (es) * 1998-11-23 2004-07-01 Novartis Ag Uso de derivados de estaurosporina para tratar enfermedades neovasculares oculares.
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
IL151045A0 (en) 2000-02-07 2003-04-10 Abbott Gmbh & Co Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
EP2319493A3 (en) * 2002-07-23 2011-07-27 Novartis AG Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
US20070059381A1 (en) * 2003-06-20 2007-03-15 Barker Ronnie C Treatment of amd with combination of ingredients
JP2007529434A (ja) * 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
BRPI0509576A (pt) 2004-04-02 2007-05-29 Osi Pharm Inc composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
AU2007286817A1 (en) * 2006-08-23 2008-02-28 Novartis Ag Use of PKC inhibitors in particular indolylmaleimide derivatives in ocular diseases
EP2089016A4 (en) * 2006-10-03 2014-10-08 Univ Pennsylvania METHOD FOR TREATING MACULAR AGENCY
US10360673B2 (en) 2015-03-26 2019-07-23 Eyekor, Llc Image analysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
IL111851A (en) * 1993-12-07 1998-09-24 Lilly Co Eli Improved synthesis of bisindolylsimilides and process for its preparation
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CN1050844C (zh) * 1993-12-07 2000-03-29 伊莱利利公司 蛋白激酶ｃ抑制剂
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
NO985067D0 (no) 1998-10-30
PT918519E (pt) 2004-10-29
NZ538109A (en) 2006-10-27
NO322209B1 (no) 2006-08-28
EP0918519B1 (en) 2004-07-07
AU724923B2 (en) 2000-10-05
EP0918519A1 (en) 1999-06-02
JP2000514402A (ja) 2000-10-31
CN1158073C (zh) 2004-07-21
HK1020017A1 (en) 2000-03-10
DE69729798D1 (de) 2004-08-12
KR100364487B1 (ko) 2003-01-25
AU2936197A (en) 1997-11-19
ES2224249T3 (es) 2005-03-01
PL330463A1 (en) 1999-05-24
NO985067L (no) 1998-12-22
BR9710705A (pt) 1999-08-17
HU226378B1 (en) 2008-10-28
EA001752B1 (ru) 2001-08-27
ATE270548T1 (de) 2004-07-15
CA2253613C (en) 2007-11-27
EA199800970A1 (ru) 1999-06-24
CN1222850A (zh) 1999-07-14
DE69729798T2 (de) 2005-08-25
IL126836A (en) 2004-05-12
JP4122060B2 (ja) 2008-07-23
NZ332833A (en) 2000-07-28
CA2253613A1 (en) 1997-11-06
KR20000065172A (ko) 2000-11-06
UA54427C2 (uk) 2003-03-17
EP0918519A4 (en) 1999-08-11
CZ296711B6 (cs) 2006-05-17
IL126836A0 (en) 1999-09-22
PL189020B1 (pl) 2005-06-30
HUP9902805A3 (en) 2000-04-28
CZ349998A3 (cs) 1999-11-17
WO1997040831A1 (en) 1997-11-06
US6114320A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
HUP9902805A2 (hu) Makrociklusos bisz(indolil))-maleinimid-származékok alkalmazása szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
CA2237221A1 (en) Protein kinase c inhibitor
CA2216535A1 (en) Protein kinase c inhibitors
AU687909B2 (en) Protein kinase C inhibitors
YU57398A (sh) Primena proteinske kinaze c inhibitora za dobijanje medikamenta za tretiranje kardiovaskularnih oboljenja
EP0829262A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of sexual dysfunctions
EP0940143A3 (en) Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma
EP0940141A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
EP0940142A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
NO990947L (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon
HUP9902315A2 (hu) Bisz(indolil)-maleinimid-csoportot tartalmazó makrociklusok alkalmazása proteinkináz-C inhibitor hatású gyógyszerkészítmények előállítására
EA199900243A1 (ru) Применение ингибиторов протеинкиназы с для производства лекарственного препарата для лечения инфекции, вызванной человеческим т-клеточным лимфотропным вирусом типа 1

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees